While biotechnology companies and academic institutions in established markets remain important sources of innovation for pharmaceutical companies looking for licensing deals and partnerships, emerging markets are becoming increasingly attractive. This is especially true as pharma companies face patent expirations and increasing competition. Join business development executives from top pharmaceutical companies who will describe their company’s strategy in partnering with companies in emerging markets; why emerging markets appeal to them; which areas they are interested in and why; and whether the criteria to evaluate potential partnerships and collaborations in emerging markets differ from other deal types. 

Learning Objectives:

  • Examine the role emerging markets play in pharma’s business development strategies
  • Discover how Big Pharma accesses and assesses innovation in emerging markets
  • Identify desirable attributes to get noticed by Big Pharma

Ability Level: All

Session ID: 1970

myBIO Chatter

Speakers (4)

contact_1381 Joshua Berlin Executive Editor Elsevier Business Intelligence
contact_4006 Shaun Grady VP and Head of SPBD AstraZeneca
contact_9679 Sophie Kornowski-Bonnet Global Head of Roche Partnering Roche
contact_270 Barbara Yanni VP & Chief Licensing Officer Merck